Date | Title | Category |
---|---|---|
13-Oct-2009 |
Caution Statement on “Increased Risk for Opportunistic Infections such as Activation of Latent Viral Infections Including BK Virus-Associated Nephropathy” required to be included in the product package insert for Immunosuppressant Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009 |
DCA letters |
22-Jul-2010 |
Caution Statement on "Boxed warning" must include Propylthiouracil with "Severe Liver Injury" Bil (55) dlm. BPFK/PPP/01/03 dated 22nd Jul 2010 |
DCA letters |
23-Feb-2011 |
Briefing on 'Competition Act 2010' by the Ms Shila Dorai Raj, Director of the Interim Competition Commission, MDTCC |
General News |
15-Sep-2009 |
Advertisement on Products for nicotine replacement therapy with MAB Approval Bil (37) dlm KKM-55/205/001/02 Jld 5 dated 15th Sept 2009 |
MAB Letter |
12-Nov-2009 |
8th List for BE Studies for Oral “Immediate Release” Generic Products Bil (46) dlm. BPFK/PPP/01/03 dated 30th October 2009 |
DCA letters |
24-Mar-2016 |
44th PhAMA Annual General Meeting 2016 |